COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

May 8, 2020

HJB and Mabspace Biosciences' Development and Manufacturing Agreement for Novel Humanized Claudin18.2 Monoclonal Antibody Accomplished FDA and NMPA IND Clearance

Sep 5, 2018

MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA

Feb 22, 2018

MabSpace Biosciences Announces FDA Approval of IND for MSB2311, a Second Generation PD-L1 Antibody With pH Dependent Antigen Binding and Recycling Property

Oct 25, 2017

MabSpace Biosciences Submits Investigational New Drug Application for its Second Generation PD-L1 Antibody With pH-Dependent Antigen Binding Property

Feb 23, 2017

MabSpace Biosciences to Present Preclinical Data on Second Generation PD-L1 Antibody with pH-Dependent Antigen Binding Property at Upcoming Inaugural ASCO-SITC Clinical Immuno-Oncology Symposium

For More Press Releases

---